Cupid shares hit ₹213 after company lifts FY27 revenue outlook past ₹660cr
Indian firm Cupid has raised its FY27 revenue guidance past ₹660 crore, driving its stock up 103% year-to-date as investors respond to expanding global demand.
Cupid has revised its FY27 revenue guidance to exceed ₹660 crore, marking an upward revision of at least 10% from its previous target of ₹600 crore. The adjustment, announced in late June, follows a robust start to the fiscal year. The company stated it is on course to post first-quarter revenue of over ₹150 crore, which it expects will rank among the strongest quarterly performances in its corporate history.
The improved financial visibility has driven significant share price appreciation. Trading at ₹213 on the National Stock Exchange, the stock has gained 7% in the past week and 41.43% over the past month. These returns stand out against a backdrop of broadly weak market sentiment, pushing the stock to a 103% gain on a year-to-date basis.
The recent surge builds on extraordinary longer-term momentum. Over the past 12 months, Cupid shares have delivered an 871.62% return. To put that in perspective, an investment of ₹1 lakh made exactly a year ago would currently be valued at ₹8.4 lakh. Looking at a three-year horizon, the stock has soared over 8,522%, turning a ₹1 lakh investment made in 2022 into approximately ₹84 lakh today.
The five-year trajectory is even more pronounced. Shares have appreciated 8,664.61% over that period, rising from just ₹2.43 apiece in July 2021. A ₹1 lakh investment held continuously over that five-year timeframe would now be worth around ₹87 lakh. For investors with shorter time horizons, a ₹1 lakh allocation made just one month ago would have grown to ₹1.33 lakh.
Management attributed the stronger full-year outlook to a diversified business model and increasing operational scale across multiple segments. A growing global opportunity pipeline and stronger order visibility across both domestic and international markets are directly supporting the revenue upgrade.
Beyond its core operations, the company is actively positioning its In Vitro Diagnostics (IVD) business for future expansion. While management has maintained a deliberately cautious stance on the IVD segment's near-term growth prospects, it highlighted that ongoing regulatory approvals, new product launches, and commercialisation efforts could eventually establish the unit as a significant long-term growth driver.
